Genomma Lab Delivers a Solid Top Line Growth of 41.6% and an Outstanding EBITDA Growth of 50.8% in 2010

GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2010 RESULTS

Mexico City, Mexico – February 23, 2011

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the fourth quarter and full year periods ended December 31, 2010. All figures included herein were prepared in accordance with Mexican Financial Reporting Standards; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican Financial Reporting Standards.

4Q10 Highlights vs. 4Q09

- Net Sales for the quarter reached Ps. 2,143.3 million, an increase of 28.6%.
- EBITDA[1] increased 53.1%, to Ps. 755.5 million, representing a 35.3% margin during the fourth quarter.
- Earnings per Share[2] increased 41.4%, to Ps. 1.02.
- International Net Sales rose 107.9%, to Ps. 396.6 million.
- Consolidated Net Income for the quarter increased 25.3%, to Ps. 471.1 million, representing a margin of 22.0% over Net Sales.
- During the fourth quarter Genomma Lab successfully launched seven products under four existing brands and two products under two New Brands[3].
- Additionally, during the fourth quarter of 2010 Genomma Lab acquired four brands. Two of these were subject to approvals from the Anti-trust Commission which were obtained in January of 2011.

[1] EBITDA is calculated by adding depreciation and amortization to the operating income.
[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.
[3] As defined below.

Contact:
Oscar Villalobos-Torres
Tel: +52 (55) 5081 0000 ext 4250
inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Full Year 2010 Highlights vs. Full Year 2009

- Net Sales reached Ps. 6,263.6 million, an increase of 41.6%.
- EBITDA[4] increased 50.8%, to Ps. 1,693.5 million, representing a 27.0% margin during 2010.
- Earnings per Share[5] increased 41.6%, to Ps. 1.02 during 2010.
- International Net Sales rose 134.8%, to Ps. 1,451.6 million, representing 23.2% of total Net Sales.
- Consolidated Net Income increased 43.8%, to Ps. 1,093.0 million, representing a margin of 17.4% over Net Sales.
- During 2010 Genomma Lab successfully launched 107 products under 21 existing brands as part of its line extension strategy.
- The Company also launched 16 products under nine New Brands[6], as part of its new product launch plan during the year.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, stated: "2010 was a year of important achievements for Genomma Lab, reaffirming its leadership in the Mexican Market and expanding its operations into new countries. The Company delivered solid revenue growth and continued improving margins. Net Sales for the whole year increased almost 42% compared to 2009, while the profitability of the Company improved significantly, reaching a 27% EBITDA margin in 2010.

This growth was mainly driven by strong performance of our Mexican operations as well as outstanding results of our International operations. One of our most encouraging accomplishments this year was becoming the number one OTC pharmaceutical Company in Mexico[7]. On the other hand, *Primer Nivel por tu Salud* positioned itself as the number three generics brand in the Mexican market.[7]

As for our International operations, we entered two markets: Brazil and the United States. The first one delivered exceptional results during 2010, positioning itself as the largest of our International operations in terms of sales, after only one year of business. The rest of our operations in Latin American countries have shown strong growth, lead by Argentina, Colombia, Peru, and Ecuador. In the United States 2010 was the year to set our footprint; dedicating these initial months to successfully establishing a client and distribution network. We expect 2011 to, once again, turn out a strong year for our International operations.

[4] EBITDA is calculated by adding depreciation and amortization to the operating income.

[5] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.

[6] As defined below.

[7] In terms of sales, according to IMS Health.

During 2010 we acquired nine brands and signed two licensing agreements. We will focus on strengthening these brands during 2011 by applying Genomma Lab's business model to increase their profitability and market share. We will also focus on our organic growth, developing and launching innovative products under premium brands. As for future acquisitions, we will continue to seek attractive opportunities to complement our existing portfolio."

Consolidated Results of Operations for the Fourth Quarter and Full Year 2010

The following table shows our condensed and consolidated results of operations, in millions of pesos (except share and per-share data), the margin for each concept as a percentage of Net Sales, as well as the variation in terms of percentage for the quarter and full year periods ended December 31, 2010 compared to the same period in 2009:

For the quarter and full year periods ended December 31, 2010 and 2009
(In millions of current Mexican pesos)

	Fourth Quarter			January to December		
	2010	2009	%Var	2010	2009	%Var
Net Sales	2,143.3	1,666.4	28.6	6,263.6	4,424.7	41.6
Gross Profit	1,504.6	1,201.4	25.2	4,449.1	3,187.1	39.6
Gross Margin	70.2%	72.1%	(1.9)	71.0%	72.0%	(1.0)
EBITDA[1]	755.5	493.3	53.1	1,693.5	1,123.3	50.8
EBITDA Margin	35.3%	29.6%	5.7	27.0%	25.4%	1.6
Operating Income	729.9	487.9	49.6	1,614.8	1,090.7	48.1
Operating Income Margin	34.1%	29.3%	4.8	25.8%	24.7%	1.1
Net Income of Majority Shareholders	461.7	377.3	22.4	1,072.6	758.7	41.4
Net Income of Majority Shareholders Margin	21.5%	22.6%	(1.1)	17.1%	17.1%	(0.0)
Weighted average number of shares outstanding[2]	1,052,608,556	1,053,078,730	(0.0)	1,052,666,686	1,054,607,134	(0.0)
EPS (12 months)[3]	1.02	0.72	41.4	1.02	0.72	41.6

[1]EBITDA is calculated by adding depreciation and amortization to the operating income.

[2]Shares outstanding for 2009 were adjusted according to the stock split made on August 3rd, 2010.

[3]Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of December 31, 2010 totaled 1,052,749,426.

Net Sales rose 28.6%, to Ps. 2,143.3 million in the fourth quarter of 2010, from Ps. 1,666.4 million in the fourth quarter of 2009. This increase resulted from the combination of the following: i) a 3.4% increase (Ps. 40.6 million) from **Base Brands** in Mexico, to Ps. 1,229.3 million, including line extensions on these brands; ii) a 31.3% increase (Ps. 89.9 million) due to the full year effect of **Prior Year Launches** in Mexico, including recent line extensions on these brands launched during 2009 to reach Ps. 376.8 million; iii) Ps. 140.6 million in the fourth quarter of 2010 from **New Brands** in Mexico due to the launch of 16 new products under nine New Brands during the year; and iv) a 107.9 % increase (Ps. 205.8 million) in **International** operations to Ps. 396.6 million.

We classify Net Sales by brands in the following manner:

1) **Base Brands** were launched at least two years prior to the last fiscal year (2008, 2007, 2006, etc),
2) **Prior Year Launches** were brands launched during the prior fiscal year (2009),
3) **New Brands** were launched in the current fiscal year (2010), and
4) **International** refers to Net Sales from our International operations.

Net Sales for the Full Year rose 41.6%, to Ps. 6,263.6 million for 2010 from Ps. 4,424.7 million for 2009. This increase resulted from the combination of the following: i) 9.4% (Ps. 279.9 million) from **Base Brands** in Mexico to Ps. 3,270.5 million, including line extensions on these brands, ii) 63.2% (Ps. 515.2 million) due to the full year effect of **Prior Year Launches** in Mexico, including recent line extensions on these brands launched during 2009, to reach Ps. 1,330.8 million, iii) Ps. 210.6 million in 2010 from **New Brands** in Mexico due to the launch of 16 new products under nine New Brands throughout the year, and iv) a 134.8% increase (Ps. 833.3 million) in our **International** operations to Ps. 1,451.6 million.

The following tables show Net Sales for 2010 and 2009 detailed by brand:

(In millions of Pesos)

BRAND	NET SALES 2010	% OF TOTAL NET SALES	NET SALES 2009	VAR %
ASEPXIA	443.6	*7.1%*	378.1	17.3%
PRIMER NIVEL	330.0	*5.3%*	344.0	-4.1%
NEXT	327.0	*5.2%*	91.2	258.4%
UNESIA	261.9	*4.2%*	66.7	292.6%
NIKZON	248.9	*4.0%*	225.4	10.4%
LINEA M	210.7	*3.4%*	259.7	-18.9%
GOICOECHEA	206.2	*3.3%*	186.6	10.5%
TIO NACHO	191.3	*3.1%*	66.1	189.4%
SHOT B	189.1	*3.0%*	106.2	78.1%
SILKA MEDIC	160.1	*2.6%*	131.6	21.7%
CICATRICURE	156.9	*2.5%*	241.6	-35.1%
X RAY	155.2	*2.5%*	124.1	25.1%
QG5	154.6	*2.5%*	125.3	23.4%
METABOL TONICS	154.0	*2.5%*	176.6	-12.8%
GENOPRAZOL	152.2	*2.4%*	142.8	6.6%
DALAY	133.7	*2.1%*	125.2	6.8%
BENGUE	130.2	*2.1%*	146.7	-11.3%
SUEROX	128.3	*2.0%*	76.4	67.8%
SUBTOTAL	3,733.9	*59.6%*	3,014.3	23.9%
OTHER BRANDS (<2%)	1078.1	*17.2%*	792.0	36.1%
TOTAL MEXICO	4,812.0	*76.8%*	3,806.3	26.4%
INTERNATIONAL	1,451.6	*23.2%*	618.4	134.8%
TOTAL	**6,263.6**	***100.0%***	**4,424.7**	**41.6%**

Gross Profit increased 25.2%, to Ps. 1,504.6 million in the fourth quarter of 2010 compared to Ps. 1,201.4 million during the fourth quarter of 2009. Gross Margin decreased 1.9 percentage points as a percentage of Net Sales, to 70.2% in the fourth quarter of 2010 compared to 72.1% for the same period of 2009. This decrease was primarily attributable to a higher cost of goods sold as a percentage of Net Sales due to a change in the mix of our products.

Gross Profit for the Full Year increased by 39.6%, to Ps. 4,449.1 million for 2010 compared to Ps. 3,187.1 million for 2009. Gross Margin decreased 1.0 percentage points as a percentage of Net Sales, to 71.0% in 2010 compared to 72.0% in 2009.

Selling, General and Administrative Expenses, as a percentage of Net Sales, decreased 6.7 percentage points, to 36.1% in the fourth quarter of 2010 from 42.8% in the fourth quarter of 2009. This decrease was mainly due to economies of scale derived mainly from a more efficient management of advertising expenses, which was achieved by the increase in sales during the period.

Selling, General and Administrative Expenses for the Full Year, as a percentage of Net Sales, decreased 2.1 percentage points, to 45.3% for 2010 from 47.4% for 2009.

Operating Income increased 49.6%, to Ps. 729.9 million in the fourth quarter of 2010 compared to Ps. 487.9 million in the fourth quarter of 2009. Operating margin increased 4.8 percentage points, as a percentage of Net Sales, to 34.1% compared to 29.3% for same period in 2009. This increase was attributable to the aforementioned decrease in the Selling, General and Administrative expenses as a percentage of Net Sales, which was partially offset by an accelerated amortization of improvement expenses in our old corporate offices and our former distribution center, since the Company moved to different locations.

Operating Income for the Full Year increased 48.1%, to Ps. 1,614.8 million for 2010 compared to Ps. 1,090.7 million for 2009. Operating margin increased 1.1 percentage points, as a percentage of Net Sales, to 25.8% for 2010 compared to 24.7% for 2009.

EBITDA increased 53.1%, to Ps. 755.5 million in the fourth quarter of 2010 compared to Ps. 493.3 million in the fourth quarter of 2009. The EBITDA margin increased 5.7 percentage points as a percentage of Net Sales, to 35.3% for the fourth quarter of 2010 from 29.6% for the fourth quarter of 2009. The EBITDA margin increase was primarily due to the aforementioned decrease in the Selling, General and Administrative Expenses as a percentage of Net Sales, which was partially offset by an increase in the cost of goods sold as a percentage of Net Sales.

EBITDA for the Full Year increased 50.8%, to Ps. 1,693.5 million for 2010 compared to Ps. 1,123.3 million for 2009. The EBITDA margin increased 1.6 percentage points as a percentage of Net Sales, to 27.0% for 2010 from 25.4% for 2009.

EBITDA Reconciliation

For the fourth quarter and full year period ended on December 31, 2010 and 2009
(In millions of current Mexican pesos)

	Fourth Quarter		Full Year	
	2010	2009	2010	2009
Consolidated net income (loss)	471.1	376.5	1,093.0	760.4
Discontinued operations	-	12.3	-	11.5
Income tax expense (benefit)	217.0	86.2	482.4	305.3
Not consolidated subsidiaries (income)	4.9	-	19.1	-
Comprehensive financing (income) cost	31.8	14.2	27.3	13.3
Other expense (income), net	5.1	(1.3)	(6.9)	0.1
Operation income	**729.9**	**487.9**	**1,614.8**	**1,090.7**
Depreciation and amortization	25.6	5.4	78.7	32.6
EBITDA	**755.5**	**493.3**	**1,693.5**	**1,123.3**
EBITDA margin	*35.3%*	*29.6%*	*27.0%*	*25.4%*

Comprehensive Financing Cost was Ps. 31.8 million for the fourth quarter of 2010, which represented an increase of Ps. 17.6 million compared to the Ps. 14.2 million financing cost reported for the fourth quarter of 2009. This increase was primarily a result of: i) an increase in financial expenses of Ps. 23.2 million, to Ps. 30.6 million during the fourth quarter of 2010 from Ps. 7.4 million during the same period of 2009, as a result of anticipated collections which we exercised with our customers in order to increase the Company's cash position so we could comply with contractual obligations derived from brand acquisitions without depending on debt; ii) a lower foreign exchange loss of Ps. 4.2 million in the fourth quarter of 2010, from a Ps. 16.1 million loss during the same period of 2009, primarily due to lower foreign cash balances during 2010; iii) a loss in the monetary position of Ps. 2.5 million in the fourth quarter of 2010 compared to a gain of Ps. 3.1 million for the fourth quarter of 2009; iv) a lower interest income of Ps. 4.5 million for the fourth quarter of 2010 from Ps. 5.1 million in the same period of 2009; and v) an increase of Ps. 0.05 million from the effects of the exchange rate in foreign operations, to a Ps. 1.1 million gain in the fourth quarter of 2010 from a Ps. 1.06 million gain during the same period of 2009. As of December 31, 2010, the Company maintained a U.S. dollar cash position of US$ 8.4 million.

Comprehensive Financing Cost for the Full Year represented Ps. 27.3 million in 2010, which was an increase of Ps. 14.0 million compared to the Ps. 13.3 million reported for the same period in 2009.

As of December 31, 2010, Genomma Lab had a total cash position, held in dollars and pesos, of Ps. 1,454.2 million.

Consolidated Net Income increased 25.3%, to Ps. 471.1 million in the fourth quarter of 2010 compared to Ps. 376.1 million in the fourth quarter of 2009. Consolidated Net Income, as a percentage of Net Sales, decreased 0.6 percentage points, to 22.0% in the fourth quarter of 2010 compared to 22.6% in the same period of 2009.

Consolidated Net Income for the Full Year increased 43.8%, to Ps. 1,093.0 million for 2010 from Ps. 760.0 million reported for 2009. Consolidated Net Income, as a percentage of Net Sales, increased 0.2 percentage points, to 17.4% for 2010 from 17.2% for 2009.

Balance Sheet

As of December 31, 2010 and December 31, 2009
(In millions of current Mexican pesos for the amounts of December 2010 and December 2009)

	December 31, 2010	December 31, 2009	Var dic '10 vs dic '09	% Var dic '10 vs dic '09	September 30, 2010	Var Dec '10 vs Sept '10	% Var Dec '10 vs Sept '10
Balance Sheet Information:							
Cash and equivalents	**1,454.2**	1,059.4	394.8	37.3%	786.3	667.9	84.9%
Trade receivables	**1,937.4**	1,336.9	600.5	44.9%	2,112.3	(174.9)	-8.3%
Inventories	**946.7**	630.1	316.5	50.2%	805.5	141.1	17.5%
Other current assets	**342.8**	340.6	2.2	0.6%	314.1	28.7	9.1%
Total Assets	**5,830.9**	4,241.7	1,589.3	37.5%	5,150.4	680.5	13.2%
Suppliers	**969.1**	594.3	374.8	63.1%	723.3	245.8	34.0%
Other current liabilities	**562.8**	427.0	135.8	31.8%	668.0	(105.2)	-15.7%
Loans with financial institutions	**-**	-	-		-	-	
Total Liabilities	**1,719.3**	1,190.9	528.3	44.4%	1,504.4	214.8	14.3%
Stockholders Equity	**4,111.6**	3,050.7	1,060.9	34.8%	3,645.9	465.7	12.8%
Working Capital (1)	**3,149.1**	2,345.7	803.4	34.3%	2,626.9	522.2	19.9%
Working Capital less cash	**1,694.9**	1,286.3	408.6	31.8%	1,840.6	(145.6)	-7.9%
Trade Recevables days	**111**	109	3	2.4%	131	(19)	-15.3%
Inventories days	**188**	183	5	2.5%	177	11	6.3%
Suppliers days	**192**	173	19	11.2%	159	33	21.1%
Cash Conversion Cycle	**107**	119	(12)	-10.3%	149	(43)	-28.5%

(1) Working capital consists of current assets minus current liabilities.

Cash and Equivalents increased 37.3% (Ps. 394.8 million), to Ps. 1,454.2 million on December 31, 2010 compared to Ps. 1,059.4 million on December 31, 2009. This increase was mainly due to the Company's cash generation of the last twelve months, which was partially offset by the cash consumption related to: i) working capital in the amount of Ps. 803.4 million; ii) Ps. 210.0 million for the acquisition and improvements made to the Company's new corporate offices; and iii) Ps. 158.8 million paid for acquisitions during 2010.

Trade Receivables increased 44.9% (Ps. 600.5 million), to Ps. 1,937.4 million on December 31, 2010 from Ps. 1,336.9 million on December 31, 2009. Days of Trade Receivables increased 2 days, to 111 days on December 31, 2010 from 109 days on December 31, 2009. Trade Receivables were benefited by the anticipated collection which was exercised with customers as a strategy to bridge a long term financing, which is being negotiated, in order to comply with contractual obligations derived from brand acquisitions.

Inventories increased 50.2% (Ps. 316.5 million), to Ps. 946.7 million on December 31, 2010 from Ps. 630.1 million on December 31, 2009. Days of Inventories increased 5 days, to 188 days on December 31, 2010 from 183 days on December 31, 2009. This change was mainly attributable to inventory increases in order to support the strong growth derived from both the Mexican and International operations.

Suppliers increased 63.1% (Ps. 374.8 million), to Ps. 969.1 million on December 31, 2010, from Ps. 594.3 million on December 31, 2009. Days of Suppliers increased 19 days, to 192 days on December 31, 2010 from 173 days on December 31, 2009. This change was mainly due to the Company acquiring strong inventories from suppliers during the last months of 2010.

Cash Conversion Cycle reached 107 days at the end of 2010, which is below the Company`s corporate target of 120 days.

Operations Summary

For the fourth quarter of 2010 Net Sales of OTC pharmaceutical products increased 9.0%[8] compared to the fourth quarter of 2009. During the fourth quarter of 2010 the Company launched one new OTC product.

For the year 2010 sales of OTC pharmaceutical products increased 29.1%[9] compared to 2009.

Net sales of personal care products increased 54.1%[10] for the fourth quarter of 2010 compared to the fourth quarter of 2009. During the fourth quarter of 2010 the Company launched eight new personal care products.

Sales of personal care products increased 30.1%[11] for 2010 compared to 2009.

Net sales of generic pharmaceutical products decreased 73.2%[12] for the fourth quarter of 2010 compared to the fourth quarter of 2009.

For 2010 sales of generic pharmaceutical products decreased 4.1%[13] compared to 2009.

[8] Includes only OTC pharmaceutical products in Mexico.
[9] Includes only OTC pharmaceutical products in Mexico.
[10] Includes only personal care products in Mexico.
[11] Includes only personal care products in Mexico.
[12] Includes only branded generic pharmaceuticals in Mexico.

Net Sales of our international operations increased 107.9%, to Ps. 396.6 million for the fourth quarter of 2010 compared to Ps. 190.8 million for the same period in 2009. This increase was due to a strong growth in our Latin American operations, mainly driven by sales from the Brazilian and Argentinean operations.

Net Sales of our International operations increased 134.8% for the Full Year 2010, to Ps. 1,451.6 million compared to Ps. 618.4 million for the same period in 2009.

International Operations represented 23.2% of our total Net Sales as of December 2010. The aforementioned increase in our International operations was mainly driven by our top 5 countries: Brazil, Argentina, Colombia, Peru, and Ecuador.

[13] Includes only branded generic pharmaceuticals in Mexico.

New Products Launches and Line Extensions

During 2010 Genomma Lab launched 107 line extensions of **Base Brands** and **Prior Year Launches;** and 16 new products under nine **New Brands**.

Among the most successful products launched are:

Henna Egipcia Shampoos and Conditioners are line extensions of our hair care brand *Henna Egipcia,* consisting of shampoos and conditioners with a touch of henna that helps maintain the hair color and brightness as you wash it. They come in 4 colors: black, chocolate, red, and blond.

Nasalub Max is also a line extension of the recently acquired brand *Nasalub*, consisting of saline water which helps the nose maintain its mucosa hydrated.

Cicatricure FPS 100 is a line extension of our skin care brand *Cicatricure*. It is a sun screen with a solar protection factor of 100 with a unique formula that protects the skin without leaving greasy or thick layers.

Other Events

- On December 10th, 2010 the Company released its 2011 earnings guidance, expecting Net Sales growth in the range of 30% to 32% for the full year 2011, and an EBITDA margin of 25.5%, based on the final results of 2010.

- During 2010 the stock showed an important improvement in its liquidity mainly driven by: i) a broader base of international and domestic investors; ii) a solid financial performance; iii) a continuous growth in Net Sales; and iv) the entrance to the Mexican Stock Exchange Index (IPC) on September 1st. As a result of the above, the Company`s stock moved 19 spots, positioning itself as the 8th most liquid company of the Mexican Stock Exchange in only 12 months.

- On January 28th, 2011 the Company, after receiving the corresponding approval from the Comisión Federal de Competencia (Mexico's Anti-trust Commission), closed the acquisition of the brands ***VanartMR, Pomada de la CampanaMR, AffairMR*** and ***GalaflexMR***. The total value of the transaction is $1,031.2 million pesos. Genomma Lab made an initial payment of $590.0 million pesos with its own resources. The Company has long term financing alternatives for the 2010 acquisitions, the details of such financing will be disclosed when it is formalized.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab counts with a combination of a successful new products development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated statements of operations

2010 and 2009
(In thousands of current Mexican pesos)

	Fourth Quarter			Full Year		
	2010	2009	% Var	2010	2009	% Var
Net sales	2,143,337	1,666,359	29%	6,263,621	4,424,655	42%
Costs and expenses:						
Cost of sales	638,771	464,973	37%	1,814,478	1,237,519	47%
Selling, general and administrative expenses	774,640	713,486	9%	2,834,352	2,096,437	35%
Total costs and expenses	1,413,411	1,178,458	20%	4,648,831	3,333,956	39%
Income from operations	729,927	487,901	50%	1,614,791	1,090,700	48%
Other (expense)- Net	(5,089)	1,291	NA	6,932	(50)	NA
Comprehensive financing income (cost)						
Interest (expense)	(30,620)	(7,394)	314%	(41,692)	(14,439)	189%
Interest income	4,485	5,136	NA	26,787	38,864	NA
Exchange gain (loss)	(4,215)	(16,145)	NA	(14,244)	(39,216)	NA
Monetary position (loss)	(2,527)	3,098	NA	(10,653)	(965)	1004%
Effects of exchange rate changes on foreign operations	1,111	1,065	4%	12,514	2,430	415%
	(31,766)	(14,241)	123%	(27,289)	(13,326)	105%
Income of not consolidated subsidiaries	(4,891)	(399)	1125%	(19,112)	(399)	4686%
Income before income taxes	688,181	474,951	45%	1,575,322	1,077,323	46%
Income tax expense (benefit)	217,045	86,182	152%	482,365	305,345	58%
Discontinued operations (loss)	-	(12,281)	NA	-	(11,543)	NA
Consolidated net income (loss)	471,136	376,488	25%	1,092,958	760,435	44%
Consolidated net income (loss)	471,136	376,488	25%	1,092,958	760,435	44%
Net loss (income) of minority stockholders	(9,404)	1,221	NA	(20,393)	(1,297)	1473%
Net income of majority stockholders	461,732	377,710	22%	1,072,565	759,138	41%
EBITDA	755,546	493,347	53%	1,693,541	1,123,304	51%
EBITDA margin	35.3%	29.6%		27.0%	25.4%	

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of December 30, 2010 and December 31, 2009.
(In thousands of current Mexican Pesos)

	Dec '10	Dec '09	V Dec '09 $	V Dec '09 %
Assets				
Current assets:				
Cash and equivalents	1,454,168	1,059,380	394,788	37%
Share buy back fund	0	8,142	(8,142)	-100%
Employee Share buy back fund	268	10,894	(10,626)	-98%
Accounts receivable-Net	2,161,860	1,545,647	616,213	40%
Inventory - Net	946,663	630,121	316,542	50%
Prepaid expenses and other current assets	70,284	75,677	(5,393)	-7%
Due from related parties	47,775	30,795	16,979	55%
Discontinued operations	3,024	3,445	(421)	-12%
Total current assets	**4,684,043**	**3,364,102**	**1,319,940**	**39%**
Equipment- net	**424,996**	**260,698**	**164,298**	**63%**
Trademarks	563,979	446,653	117,326	26%
Investments in subsidiaries	5,189	25,166	(19,978)	-79%
Deferred income tax	7,024	2,869	4,155	145%
Other assets- Net	145,679	142,163	3,516	2%
	721,871	**616,851**	105,020	17%
Total Assets	**5,830,909**	**4,241,651**	**1,589,258**	**37%**
Current Liabilities:				
Trade accounts payable	969,099	594,279	374,820	63%
Due to related parties	-	81	(81)	-100%
Accrued expenses and taxes other than income taxes	384,019	389,295	(5,275)	-1%
Payable tax (2)	178,799	37,640	141,159	375%
Statutory employee profit sharing	11,738	3,382	8,355	247%
Discontinued operations	4,087	4,656	(569)	-12%
Deferred income tax	67,223	46,006	21,216	46%
Employee retirement obligations	10,003	7,491	2,512	34%
Trade accounts payable LP	94,295	108,090	(13,795)	-13%
Total Liabilities	**1,719,263**	**1,190,920**	**528,343**	**44%**
Capital stock	1,931,222	274,924	1,656,299	602%
Additional paid in capital	-	1,553,938	(1,553,938)	-100%
Retained earnings	1,141,685	1,278,375	(136,690)	-11%
Net income	1,072,569		1,072,569	100%
Cumulative translation effects of foreign subsidiaries	(6,636)	1,228	(7,864)	-640%
Share buyback fund (1)	(54,285)	(66,686)	12,400	-19%
Interés minoritario	27,090	8,953	18,137	203%
Total stockholders equity	**4,111,647**	**3,050,731**	**1,060,915**	**35%**

Cash Flow Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated Cash Flow
For the full year and fourth quarter of 2010
(In thousands of current Mexican pesos)

	Accumulated 2010	4Q 2010
Operating activities:		
Consolidated income for continued operations	1,092,958	471,135
Items related to non investing activities:		
Depreciation and amortization	78,750	25,620
Unearned foreign exchange fluctuations	(159)	(273)
Gain on fixed assets sale	765	1,322
Income tax	482,365	217,045
Equity in loss of associated companies	19,112	4,891
Cash flow from operations	**1,673,790**	**719,739**
(Increase) Decrease in accounts receivable	(850,132)	70,516
(Increase) Decrease in inventories	(317,088)	(141,229)
Increase (Decrease) in accounts payable	374,893	92,791
Increase (Decrease) in payable income tax	(134,984)	(25,514)
Other, Net	81,350	44,767
Stock-based compensations cost	25,065	1,494
Discontinued operations	(147)	(38)
Changes in Working Capital	**(821,043)**	**42,787**
Net cash generated (used) in operating activities	**852,747**	**762,526**
Net Cash flow used in operating activities after discontined operations	**852,747**	**762,526**
Investing activities:		
Divestments (investments) in fixed assets	(226,122)	(37,118)
Asset sales (other capital expenditures)	(195,334)	(55,990)
Discontinued operations	-	-
Net cash generated (used) in investing activities	**(421,456)**	**(93,108)**
Excess cash for (cash obtained from) financing activities	**431,292**	**669,419**
Financing activities:		
Equity increase / Paid in capital	-	-
Sale (Repurchase) of stocks	(46,990)	(5,950)
Borrowings with financial institutions	-	-
Minority interest	(2,255)	(96)
Net cash used in financing activities	**(49,246)**	**(6,047)**
International operations and inflationary effects.	**382,046**	**663,372**
Foreign exchange and inflationary effects from International operations	**(6,025)**	**(401)**
Net increase (decrease) in cash	**376,021**	**662,971**
Cash and cash equivalents beginning of period	**1,078,416**	**791,466**
Cash and cash equivalents end period balance	**1,454,437**	**1,454,437**
less- Employees' shares fund	-	-
less- shares buyback fund	269	269
Cash and cash equivalents at end period balance for operation	**1,454,168**	**1,454,168**